Oct 13 (Reuters) - Palvella Therapeutics Inc PVLA.O:
U.S. FOOD AND DRUG ADMINISTRATION AWARDS YEAR TWO PROCEEDS FROM ORPHAN PRODUCTS GRANT SUPPORTING PALVELLA THERAPEUTICS’ PHASE 3 SELVA TRIAL OF QTORIN™ RAPAMYCIN FOR MICROCYSTIC LYMPHATIC MALFORMATIONS
PALVELLA THERAPEUTICS INC - TOP-LINE DATA FROM SELVA EXPECTED Q1 2026; NDA SUBMISSION H2 2026